02042nas a2200229   4500000000100000008004100001653000900042653002500051653002900076653001300105653001500118653002300133653001400156100001500170700001500185245010800200856006600308300001400374490000600388520140400394022001401798       2017                            d10aNTDs10aLymphatic filariasis10aMass drug administration10aCoverage10aCompliance10aDiethylcarbamazine10aKalaburgi1 aBiradar MK1 aHolyachi S00aCoverage and compliance of mass drug administration against lymphatic filariasis in Kalaburgi district.  uhttp://www.ijcmph.com/index.php/ijcmph/article/view/1458/1271  a2502-25050 v43 a<p><strong>Background: </strong>Lymphatic filariasis (LF) is endemic in 83 countries and territories, with more than a billion people at risk of infection. Filariasis has been a major public health problem in India next only to malaria. Study was done to assess coverage and compliance of mass drug administration (MDA) against lymphatic filariasis in Kalaburgi districts. <strong>Methods: </strong>This cross-sectional coverage evaluation survey was done in one urban and three rural clusters in district. The data was compiled, tabulated and analyzed using proportions. <strong>Results: </strong>A total of 791 subjects were interviewed, male subjects constituted about 47.7%. Majority of the subjects were in the age group of 16-60 years (69.9%), while only 3.2% were in &lt;2years. 82.9% persons have received the drugs. Out of the 530 persons who have received the drugs, 86.9% persons have consumed the drugs. Only 59.9% of study subjects consumed tablets in front of health workers. A total of 69 subjects have not consumed tablets, 20.3% said told fear of side reaction, and 20.3% subjects said they don’t have faith in tablet. Only 11 persons suffered from vomiting and nausea. <strong>Conclusions: </strong>There is an urgent need for more effective drug delivery strategies and also proper IEC should be done to educate and to improve the coverage and compliance in the districts.</p>
  a2394-6032